Get the Stockscreener App
9.97
1.42%
0.14
Allovir Inc stock is traded at $9.97, with a volume of 110.
It is up +1.42% in the last 24 hours and up +6.29% over the past month.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
See More
Previous Close:
$9.83
Open:
$9.97
24h Volume:
110
Relative Volume:
0.00
Market Cap:
$49.56M
Revenue:
-
Net Income/Loss:
$-168.86M
P/E Ratio:
-5.9345
EPS:
-1.68
Net Cash Flow:
$-125.29M
1W Performance:
+0.71%
1M Performance:
+6.29%
6M Performance:
-43.65%
1Y Performance:
-39.13%
1-Day Range:
$9.97
$9.97
1-Week Range:
$9.55
$10.41
52-Week Range:
$7.96
$24.15
Allovir Inc Stock (ALVR) Company Profile
Name
Allovir Inc
Sector
Industry
Phone
(617) 433-2605
Address
1100 WINTER STREET, WALTHAM
Compare ALVR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALVR
Allovir Inc
|
9.97 | 49.56M | 0 | -168.86M | -125.29M | -1.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.80 | 123.34B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
696.80 | 76.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
647.78 | 39.34B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.22 | 32.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
117.21 | 28.26B | 3.30B | -501.07M | 1.03B | -2.1146 |
Allovir Inc Stock (ALVR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-26-23 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-22-23 | Downgrade | JP Morgan | Overweight → Underweight |
| Dec-22-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-22-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-18-23 | Initiated | BofA Securities | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Aug-24-20 | Initiated | JP Morgan | Overweight |
| Aug-24-20 | Initiated | Morgan Stanley | Overweight |
| Aug-24-20 | Initiated | SVB Leerink | Outperform |
View All
Allovir Inc Stock (ALVR) Latest News
ALVR SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds AlloVir Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
UPCOMING ALVR DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds AlloVir Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
$TOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of EMKR, CCRN, WMPN, ALVR to Act Now - GlobeNewswire Inc.
(ALVR) Technical Pivots with Risk Controls - Stock Traders Daily
AlloVir (NASDAQ:ALVR) Stock Price Up 0.5%Should You Buy? - MarketBeat
IMMINENT ALVR DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds AlloVir Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc.ALVR - Business Wire
AlloVir (NASDAQ:ALVR) Stock Price Up 0.5% – Should You Buy? - Defense World
$TOCKHOLDER ALERT: The M&A Class Action Firm Urges Shareholders of OMIC, BERY, WMPN, ALVR to Act Now - The Malaysian Reserve
Allovir director Vikas Sinha sells $1,225 in stock - MSN
Allovir's chief accounting officer sells $342 in common stock - MSN
Allovir's general counsel sells $494 in stock - MSN
Allovir's general counsel sells $494 in stock By Investing.com - Investing.com South Africa
Allovir's chief accounting officer sells $342 in common stock By Investing.com - Investing.com South Africa
Allovir director Vikas Sinha sells $1,225 in stock By Investing.com - Investing.com Australia
Levi & Korsinsky Notifies Shareholders of AlloVir, Inc.(ALVR) of a Class Action Lawsuit and an Upcoming Deadline - GuruFocus.com
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The MergerCYTH, ALVR, WMPN, OMC - Morningstar
ALVR LAWSUIT ALERT: Levi & Korsinsky Notifies AlloVir, Inc. Inve - GuruFocus.com
AlloVir (NASDAQ:ALVR) Trading 8.2% HigherHere's What Happened - MarketBeat
The Law Offices of Vincent Wong Remind AlloVir Investors of a Lead Plaintiff Deadline of March 19, 2024 - Marketscreener.com
Shareholders that lost money on AlloVir, Inc.(ALVR) should contact Levi & Korsinsky about pending Class ActionALVR - Marketscreener.com
AlloVir (NASDAQ:ALVR) Hits New 1-Year LowWhat's Next? - MarketBeat
SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options - Marketscreener.com
Shareholder Alert: Ademi LLP Investigates Whether AlloVir, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Marketscreener.com
AlloVir, Inc. Enter into Termination of Sublease Agreement with AMAG Pharmaceuticals, Inc - Marketscreener.com
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir - Marketscreener.com
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 19, 2024 in AlloVir, Inc. LawsuitALVR - Marketscreener.com
Jane Street Group LLC Sells 89,680 Shares of AlloVir, Inc. (NASDAQ:ALVR) - Defense World
AlloVir executes reverse stock split By Investing.com - Investing.com Australia
AlloVir executes reverse stock split - Investing.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Allovir's general counsel Edward Miller sells $180 in stock - Investing.com India
Allovir stock plunges to 52-week low, touches $0.4 By Investing.com - Investing.com Canada
Allovir’s Vikas Sinha sells shares worth $430 By Investing.com - Investing.com Nigeria
Allovir's Vikas Sinha sells shares worth $430 By Investing.com - Investing.com Australia
Allovir’s general counsel Edward Miller sells $180 in stock By Investing.com - Investing.com Nigeria
Allovir’s chief accounting officer sells $146 in common stock By Investing.com - Investing.com Nigeria
Allovir's chief accounting officer sells $146 in common stock By Investing.com - Investing.com Australia
Allovir's general counsel Edward Miller sells $180 in stock By Investing.com - Investing.com Australia
Allovir's chief accounting officer sells $146 in common stock - Investing.com India
Allovir stock plunges to 52-week low, touches $0.4 - Investing.com India
Allovir Inc Stock (ALVR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):